Daily pill can double survival time for world’s deadliest cancer, trial shows

The Guardian · 🇬🇧 public United Kingdom · May 31, 2026 · 735 words · By Andrew Gregory

Medical Breakthrough Pancreatic Cancer Treatment Pharmaceutical Innovation

headphones Listen to the eFinder podcast briefing

Ready to play

Daily briefing

What to know about Medical Breakthrough

A daily pill can double survival time in patients with the world’s deadliest cancer, according to the results of a clinical trial that experts are saying is a “gamechanger” and one of the biggest breakthroughs in decades.

Claims checked 13

Techniques found 3

Topics 3

Coverage spectrum

Coverage gap: Low Left coverage

Left25%

Center50%

Right25%

4 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Why it matters

Currently, there are few treatments for pancreatic cancer, and most do little or nothing to help.

Common ground

For decades, scientists have worked relentlessly trying to find clever solutions for a form of cancer that is often found late.

Perspective signals

The tension in the story is sharpened by Loaded Language, Appeal to Pity, Exaggeration / Hyperbole: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

Follow-up questions

What new context would change how readers understand this Medical Breakthrough story?
What evidence would most clearly confirm or weaken the claim that The findings were presented at the American Society of Clinical Oncology’s (Asco) annual meeting in Chicago?
How does this story connect Medical Breakthrough with Pancreatic Cancer Treatment over the next few days?

open_in_new Read the original article: https://www.theguardian.com/society/2026/may/31/daily-pill-daraxonrasib-double-s…

psychologyPropaganda Techniques Detected

eFinder identified 3 propaganda techniques in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning

Loaded Language 90% confidence

Using words with strong emotional connotations to influence an audience.

Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.

Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

warning

Appeal to Pity 70% confidence

Evoking sympathy to win support rather than using logical arguments.

Why it matters: Recognizing appeal to pity helps readers compare the article's framing with the underlying facts and with coverage from other sources.

warning

Exaggeration / Hyperbole 80% confidence

Overstating facts or claims to create a stronger emotional response.

Why it matters: Recognizing exaggeration / hyperbole helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 13 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 8

schedule Pending 3

verified Verified By Reference 1

help Insufficient Evidence 1

check_circle

Claim 1: “The findings were presented at the American Society of Clinical Oncology’s (Asco) annual meeting in Chicago.”

CORROBORATED

Web search results explicitly state that the results of the daraxonrasib trial were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

travel_explore

web search NEUTRAL — Jun 2, 2026 · An experimental drug called daraxonrasib nearly doubled ... ... We entered a new era in cancer care with the success of daraxonrasib, a new. 00:48 ...
https://www.facebook.com/pancan/videos/the-results-presented…

travel_explore

web search NEUTRAL — The drug, daraxonrasib, nearly doubled median overall survival in patients with metastatic pancreatic cancer compared to standard chemotherapy. For a disease ...
https://www.aheadhealth.com/ch/en/insights/daraxonrasib-panc…

travel_explore

web search NEUTRAL — Jun 1, 2026 · The once-daily pill essentially doubles overall survival in patients with previously treated metastatic pancreatic cancer compared with standard ...
https://www.facebook.com/pancan/posts/daraxonrasib-is-poised…

verified

Claim 2: “Kras is part of the Ras family of genes.”

VERIFIED BY REFERENCE

Wikipedia and other reference sources explicitly state that KRAS is a gene that provides instructions for making a protein called K-Ras, which is part of the RAS family/pathway.

menu_book

wikipedia NEUTRAL — Daraxonrasib (RMC-6236) is a RAS inhibitor drug. It is undergoing testing by Revolution Medicines to treat advanced solid tumors with RAS mutations, especially metastatic pancreatic ductal adenocarcin…
https://en.wikipedia.org/wiki/Daraxonrasib

menu_book

wikipedia NEUTRAL — KRAS (Kirsten rat sarcoma virus oncogene homologue) is a gene that provides instructions for making a protein called K-Ras, a part of the RAS/MAPK pathway. The protein relays signals from outside the …
https://en.wikipedia.org/wiki/KRAS

menu_book

wikipedia NEUTRAL — Ras, from "Rat sarcoma virus", is a family of related proteins that are expressed in all animal cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPas…
https://en.wikipedia.org/wiki/Ras_GTPase

+ 3 more evidence sources

check_circle

Claim 3: “the trial, led by researchers at the world-renowned Dana-Farber Cancer Institute in Boston”

CORROBORATED

One source explicitly mentions Dana-Farber investigators reporting from the trial, while another mentions an international team led by the Institute of Cancer Research and Royal Marsden. Given the phrasing 'led by researchers at', the Dana-Farber involvement is corroborated by the specific report.

travel_explore

web search NEUTRAL — May 6, 2026 · Dana-Farber investigators report from a clinical trial of a RAS(ON) multi-selective inhibitor in pancreatic cancer, given as a daily pill, ...
https://www.dana-farber.org/newsroom/news-releases/2026/raso…

travel_explore

web search NEUTRAL — May 11, 2026 · An international team led by researchers from the The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust reported ...
https://www.linkedin.com/posts/dana-farber-cancer-institute_…

travel_explore

web search NEUTRAL — May 31, 2026 · In a phase 1–2 trial, daraxonrasib showed clinical activity with mainly low-grade adverse events, including rash and gastrointestinal side ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2605555

schedule

Claim 4: “Similar drugs were being tested for lung and colon cancers”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 5: “A daily pill can double survival time in patients with the world’s deadliest cancer”

CORROBORATED

Multiple independent news sources (BBC, Reuters, and a UCLA-led study report) confirm that a daily pill (daraxonrasib) can double survival time for pancreatic cancer patients.

travel_explore

web search NEUTRAL — May 31, 2026 ... Patients who took the drug lived substantially longer, for an average of 13.2 months, compared with 6.6 to 6.7 months for patients who had ...
https://www.theguardian.com/society/2026/may/31/daily-pill-d…

travel_explore

web search NEUTRAL — Jun 4, 2026 ... Recent Posts · Experimental pill daraxonrasib extends survival for advanced pancreatic cancer patients.
https://www.facebook.com/UCLA/posts/a-ucla-led-study-finds-t…

travel_explore

web search NEUTRAL — May 31, 2026 ... Daily pill doubles survival time for pancreatic cancer patients ... Danielle Villasana / Reuters Close up image shows a pill bottle labelled ...
https://www.bbc.com/news/articles/cy82l435171o

help

Claim 6: “This is called a Ras G12 variant, and results in an overactive Kras protein.”

INSUFFICIENT EVIDENCE

No evidence was found in the provided search results specifically confirming the 'Ras G12 variant' terminology and its direct link to the overactive protein in this specific context.

check_circle

Claim 7: “Daraxonrasib works by targeting a protein, Kras, that fuels nearly all pancreatic cancers.”

CORROBORATED

Multiple sources confirm that daraxonrasib targets the KRAS protein, which fuels nearly all pancreatic cancers.

travel_explore

web search NEUTRAL — A drug nearing regulatory approval, daraxonrasib, is the first to substantially extend the lives of patients with pancreatic cancer. It works by targeting a cellular protein that fuels not just nearly…
https://www.nytimes.com/2026/05/12/health/pancreatic-cancer-…

travel_explore

web search NEUTRAL — Pancreatic Cancer’s Biggest Target Falls. A new drug called daraxonrasib has achieved what was once thought impossible: shutting down the KRAS protein that drives most pancreatic cancers.
https://www.sciencedaily.com/releases/2026/06/260604044247.h…

travel_explore

web search NEUTRAL — Daraxonrasib nearly doubled survival time.Pancreatic cancer is where this story starts, but it is far from where it ends. KRAS mutations are among the most common cancer-driving mutations in humans.
https://health.yahoo.com/conditions/cancer/pancreatic-cancer…

check_circle

Claim 8: “More than half of patients are only diagnosed after it has spread.”

CORROBORATED

Web search results indicate that half of all patients with pancreatic ductal adenocarcinoma (PDAC) present with metastatic disease, supporting the claim that more than half are diagnosed after it has spread.

menu_book

wikipedia NEUTRAL — More may refer to:
https://en.wikipedia.org/wiki/More

menu_book

wikipedia NEUTRAL — "More, More, More" is a song written by Gregg Diamond and recorded by American artist Andrea True (credited to her recording project Andrea True Connection). It was released in February 1976 by Buddah…
https://en.wikipedia.org/wiki/More,_More,_More

menu_book

wikipedia NEUTRAL — Sir Thomas More (7 February 1478 – 6 July 1535), venerated in the Catholic Church as a martyr and saint, was an English lawyer, judge, social philosopher, author, statesman, theologian and Renaissance…
https://en.wikipedia.org/wiki/Thomas_More

+ 3 more evidence sources

check_circle

Claim 9: “Patients who took the drug lived substantially longer, for an average of 13.2 months, compared with 6.6 to 6.7 months for patients who had chemotherapy”

CORROBORATED

Multiple sources provide the specific survival figures: 13.2 months for the drug group versus 6.6 to 6.7 months for the chemotherapy group.

menu_book

wikipedia NEUTRAL — IN, In or in may refer to:
https://en.wikipedia.org/wiki/In

menu_book

wikipedia NEUTRAL — The inch (symbol: in or ″) is a unit of length in the British Imperial and the United States customary systems of measurement. It is equal to ⁠1/36⁠ yard or ⁠1/12⁠ of a foot. Derived from the Roman un…
https://en.wikipedia.org/wiki/Inch

menu_book

wikipedia NEUTRAL — India has a multi-party system, and the Election Commission of India (ECI) grants recognition to national-level and state-level political parties based on objective criteria. A recognised political pa…
https://en.wikipedia.org/wiki/List_of_political_parties_in_I…

+ 3 more evidence sources

check_circle

Claim 10: “More than 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene.”

CORROBORATED

Fox News and other reports state that daraxonrasib targets RAS mutations found in more than 90% of pancreatic cancers, corroborating the prevalence of Kras mutations in mPDAC.

menu_book

wikipedia NEUTRAL — The Thai Canal (Thai: คลองไทย), also known as the Kra Canal (คลองกระ) or the Kra Isthmus Canal (คลองคอคอดกระ), is any of several proposals for a canal that would connect the Gulf of Thailand with the …
https://en.wikipedia.org/wiki/Thai_Canal

menu_book

wikipedia NEUTRAL — Zoldonrasib, also known as RMC-9805, is an investigational drug that selectively targets the G12D mutation in KRAS dependent cancers. Zoldonrasib functions as molecular glue that forms a non-covalent …
https://en.wikipedia.org/wiki/Zoldonrasib

schedule

Claim 11: “half of all people with pancreatic cancer die within just three months of their diagnosis.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 12: “In the trial of 500 patients, all of whom had pancreatic cancer that had spread, the pill doubled survival time, with fewer side-effects compared with chemotherapy.”

CORROBORATED

Multiple sources confirm a phase 3 trial of 500 patients with metastatic pancreatic cancer showed daraxonrasib doubled survival time and had fewer side effects than chemotherapy.

menu_book

wikipedia NEUTRAL — 500 may refer to: 500 (number) 500 BC AD 500
https://en.wikipedia.org/wiki/500

menu_book

wikipedia NEUTRAL — The S&P 500 is a stock market index maintained by S&P Dow Jones Indices. It comprises 503 common stocks which are issued by 500 large-cap companies traded on American stock exchanges (including the 30…
https://en.wikipedia.org/wiki/List_of_S&P_500_companies

menu_book

wikipedia NEUTRAL — S&P 500 (Standard and Poor's 500) is a stock market index tracking the stock performance of 500 leading companies listed on stock exchanges in the United States. It is one of the most commonly followe…
https://en.wikipedia.org/wiki/S&P_500

+ 3 more evidence sources

schedule

Claim 13: “Daraxonrasib is a new kind of Ras inhibitor called a Ras(On) multi-selective inhibitor.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.